Scholars Central

Conference abstractPublished 21 Oct 2013

Regulatory environment and process in Turkey

Authors: Cigdem Yilmaz

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Turkey is a developing and emerging country which ranks as the 16th largest pharmaceutical manufacturer worldwide and the 6th largest in Europe and expected to rise in the upcoming years. The government released its action plan in 2012 for the pharmaceutical industry key highlights were to increase R&D expenditures, export activities and investment possibilities. The healthcare system in Turkey has gone through a serious reform process with the 2003-2013 health transformation program. Many regulations changed, one of the most significant changes was implemented in Aug 2009; it was the obligation of GMP inspection of import products by Turkish inspectors. Due to unbalanced ratio of import products vs. local products and global budget the government implemented such a requirement before new submissions.The government supports local manufacturing and therefore since 2009 the number of import registrations decreased significantly (in 2012, 74% local registrations 26% import registrations.) Turkey?s pharmaceutical regulations are generally in line with EU however there are some national deviations which may be a challenge for global companies. CTD format is applicable for the submission and the product is evaluated under several commissions once it is submitted such as advisory, technology, pharmacology, analysis of samples. Price can be submitted in parallel during registration phase or right after. In theory, registration process ends in 210 days however this is not the general case in practice. The recent examples show that it takes 15 months to three years. Despite many challenges such as regulation implementation without a reasonable transition period and price cuts, there are still opportunities as its one of the fastest growing markets with its 75 million populations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Cigdem Yilmaz”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels